Life Science Investing Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic , and Pharmacodynamic Data
Life Science Investing Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
Life Science Investing Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study
Life Science Investing Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Life Science Investing Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Life Science Investing Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
Life Science Investing Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
Life Science Investing Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Locksley Strengthens U.S. Defense Supply Chain Strategy with Appointment of Lockhead Martin Materials Leader to Advisory Board
